CA9 and colonic neoplasm: More recently, the Spidel team has generated two optimized scFv-auristatin F conjugates with a DAR of 2, targeting CA9, exhibiting similar efficacy with an EC50 of 0.57 and 0.81 nM on colon cancer cells HT116- CA9 [77].